Search

Displaying results 9581 - 9590 of 9617 in total
  1. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

  2. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  3. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

  4. Drug

    YSIL6

    go.drugbank.com/drugs/DB05017
    Experimental

    The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

  5. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.

  6. Drug

    CEQ508

    go.drugbank.com/drugs/DB17911
    Experimental

    CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.

  7. Drug

    RTL-1000

    go.drugbank.com/drugs/DB17946
    Investigational

    RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.

    Synonyms: Recombinant t-cell receptor ligand rtl-1000, Rtl-1000 (recombinant t-cell receptor ligand)
  8. Drug

    GMI-1359

    go.drugbank.com/drugs/DB18092
    Investigational

    GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.[A261406]

  9. Drug

    Xaluritamig

    go.drugbank.com/drugs/DB18137
    Investigational

    Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.

  10. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).